



US005932208A

United States Patent [19]

[11] Patent Number: **5,932,208**

Chedid et al.

[45] Date of Patent: ***Aug. 3, 1999**

[54] **COMPOSITIONS AND METHODS FOR THE USE OF SUCH COMPOSITIONS IN HUMAN THERAPEUTICS, CHARACTERIZED BY THE ASSOCIATION OF A MURAMYL PEPTIDE WITH A CYTOKINE**

[75] Inventors: **Louis Chedid**, Paris; **Georges Bahr**, Puteaux; **Pierre Lefrancier**, Gif sur Yvette, all of France

[73] Assignee: **Vacsyn S.A.**, Paris, France

[*] Notice: This patent issued on a continued prosecution application filed under 37 CFR 1.53(d), and is subject to the twenty year patent term provisions of 35 U.S.C. 154(a)(2).

[21] Appl. No.: **08/522,342**

[22] PCT Filed: **Mar. 21, 1994**

[86] PCT No.: **PCT/FR94/00307**

§ 371 Date: **Nov. 13, 1995**

§ 102(e) Date: **Nov. 13, 1995**

[87] PCT Pub. No.: **WO94/21275**

PCT Pub. Date: **Sep. 29, 1994**

[30] **Foreign Application Priority Data**

Mar. 19, 1993 [FR] France 93 03230
Mar. 31, 1993 [FR] France 93 03787

[51] **Int. Cl.⁶** **A61K 45/05**; A61K 38/21; A01N 61/00; C07K 1/00

[52] **U.S. Cl.** **424/85.1**; 424/85.2; 424/85.4; 514/1; 514/2; 530/350

[58] **Field of Search** 514/1, 2; 530/350; 424/85.1, 85.2, 85.4

[56] **References Cited**

FOREIGN PATENT DOCUMENTS

0 228833 7/1987 European Pat. Off. .
0 257890 3/1988 European Pat. Off. .
0 329609 8/1989 European Pat. Off. .

OTHER PUBLICATIONS

Chemical Abstracts 115:222927q (1991).
Chemical Abstracts 112:229333q (1990).
Chemical Abstracts 112:176682u (1990).
Chemical Abstracts 118:73306u (1993).
Malik et al., Br. J. Cancer, 63, 399-403 (1991).
Wyde et al., J. Bio. Response Modifiers, 9, 98-102 (1990).
Azuma et al., Adv. Exper. Med. & Biology, 319, 253-263 (1992).
Pouillart et al., J. Interferon Research, 11, p. S162 (1991).
Pouillart et al., J. Interferon Research, 11, p. S257 (1991).
Sanceau et al., Immunology, 69, 52-56 (1990).

Primary Examiner—Ardin H. Marschel
Assistant Examiner—Jezia Riley
Attorney, Agent, or Firm—Birch, Stewart, Kolasch and Birch, LLP

[57] **ABSTRACT**

A therapeutical composition for use in humans, comprising a combination of at least one natural or recombinant and preferably human cytokine with at least one muramyl peptide selected from those which, when administered in vivo together with an interferon, also induce an increased in vivo production of an interleukin-1 receptor antagonist IL-1 RA, but preferably do not induce any increase in TNE, IL-8 and IL-1 cytokines. Said composition is useful for antiviral and antitumoral therapies and/or for promoting restoration of the haematopoietic system, particularly in individuals with a weakened immune system.

30 Claims, No Drawings